Medtronic Raises 2027 Forecasts Amid Rising Heart Device Demand

Medtronic has revised its fiscal 2027 revenue and profit forecasts upward, citing a surge in demand for its heart devices used in complex cardiovascular procedures. The company now anticipates annual organic revenue growth between 7.25% and 7.75%, up from the previously expected range of 6.75% to 7.25%. The adjusted per share profit forecast's lower end was also raised to $5.94 from $5.90, while the upper end remains at $6.

Strategic Investments in Medical Technology

In a strategic move to bolster its portfolio, Medtronic announced an $80 million investment in Pi-Cardia, a heart-valve repair device maker, with an option to acquire the company for $210 million. Additionally, Medtronic invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select markets outside the United States. CEO Geoff Martha highlighted the growing importance of soft tissue robotic surgery, particularly in emerging markets, where penetration remains below 1%.

Strong Performance Across Segments

Medtronic's cardiovascular segment reported a notable 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was primarily driven by an 88% increase in sales from its pulsed field ablation portfolio, designed for treating irregular heart rhythms. The company posted an adjusted quarterly per share profit of $1.45 on revenues of $9.76 billion, surpassing estimates of $1.39 per share on $9.55 billion in sales, according to LSEG data.

Future Outlook and Market Confidence

Medtronic's CFO Thierry Pieton mentioned that the company received tariff refunds that almost offset the duties paid during the quarter. However, future refunds have not been factored into the company's outlook. CEO Martha expressed confidence in the company's performance, emphasizing the contributions from newer growth platforms and a steady cadence of mergers and acquisitions, focusing on high-growth segments with large patient pools.